Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia

Said, Mas Ayu; Hatim, Ahmad; Habil, Mohamad Hussain; Zafidah, Wan; Haslina, M.Y.; Yahya, Badiah; Ramli, Musa; Ananjit, S.; Sapini, Y.; Shah, Mohd Abas; Mahmud, Badli; Bulgiba, Awang; Hairi, Noran Naqiah

doi:10.1016/j.ypmed.2013.01.005

Cited by 10 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is worth noting that in our sample there were more Arabs in the antipsychotics group while in the control group the majority were non-Arabs, which could explain this variability between the two groups. Still ethnicity/nationality showed significant variations in the prevalence of MetS in patients with mental illness and maintained on antipsychotics [ 5 , 13 , 14 , 24 – 27 ].…”

Section: Discussionmentioning

confidence: 99%

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

et al. 2018

View full text Add to dashboard Cite

BackgroundMetabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS.MethodsA cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group.ResultsThe two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group.ConclusionsThe prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

show abstract

Section: Discussionmentioning

confidence: 99%

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Este resultado é ratificado por outro estudo semelhante realizado em Singapura (35). O uso de antipsicóticos atípicos, principalmente de clozapina, está relacionado ao aparecimento de complicações metabólicas, incluindo alteração no perfil lipídico (31,36). A elevação dos níveis de triglicérides é um importante indicador de resistência à insulina e serve como um valioso marcador para avaliar pacientes com potencial risco para distúrbios metabólico, notadamente com esquizofrenia refratária (37).…”

Section: Resultsunclassified

Prevalência De Síndrome Metabólica Em Pacientes Com Esquizofrenia Refratária

et al. 2016

View full text Add to dashboard Cite

RESUMOObjetivo: Estimar prevalência de síndrome metabólica (SM) e seus fatores associados em pacientes com esquizofrenia refratária em uso do antipsicótico clozapina. Método: Trata-se de um estudo descritivo e transversal, realizado na Região Ampliada Oeste do Estado de Minas Gerais (MG), em 2015, com uma amostra de 72 pacientes. Foram coletados dados sociodemográficos, clínicos, antropométricos e bioquímicos. Realizou-se análise descritiva, univariada e multivariada. Resultados: Observou-se prevalência de SM em 47,2% da amostra, com predomínio entre as mulheres (58,8%). Pacientes com SM apresentaram percentuais mais elevados de alterações, principalmente em relação à glicemia e triglicérides. O uso de quatro ou mais medicamentos e a presença de sobrepeso e obesidade estiveram associados à SM. Além disso, pacientes com a síndrome apresentaram um histórico de menos internações psiquiátricas, comparados àqueles que não a possui. Conclusão: A prevalência de SM encontrada nos pacientes com esquizofrenia refratária foi elevada e alarmante. A presença de sobrepeso e obesidade e o uso de 4 ou mais medicamentos podem estar associados com o desenvolvimento de SM neste grupo. Essa taxa pode representar um importante indicador de risco cardiovascular, sendo sugerida a construção de estratégias de prevenção primária das alterações metabólicas, bem como se indica que o paciente seja acompanhado periodicamente, principalmente em relação aos componentes da SM.

show abstract

“…Indeed, previous outpatient studies have pointed out that olanzapine and clozapine present the highest risk for metabolic side effects [12,35,42]. In schizophrenic patients in monotherapy, the reported prevalence rate for MetS in haloperidol-treated subjects was 37.5%, in contrast to a prevalence rate of 50.9% obtained with olanzapine treatment [43]. Our findings demonstrate that both antipsychotic treatments had a remarkable effect in inducing metabolic changes in schizophrenic and bipolar patients, although it was more prominent in the bipolar group.…”

Section: Discussionmentioning

confidence: 99%

Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients

Fabrazzo¹,

Monteleone²,

Prisco³

et al. 2015

Neuropsychobiology

View full text Add to dashboard Cite

The effects of olanzapine and haloperidol on metabolic parameters in bipolar patients have been evaluated much less comprehensively than in schizophrenic patients. Therefore, in this study, medical records of 343 schizophrenic and bipolar patients treated with haloperidol or olanzapine for 1 year were retrospectively reviewed and metabolic outcomes were evaluated. After 12 months of follow-up, 25.9% of patients showed ≥3 metabolic abnormalities with a point prevalence of 27.2% in the bipolar and 24.9% in the schizophrenic group: 22.0% of the schizophrenic patients treated with haloperidol and 29.8% of those treated with olanzapine achieved ≥3 metabolic alterations; in bipolar patients, these percentages were 15.8% of those treated with haloperidol and 37.8% of those treated with olanzapine (p < 0.0001). Significant changes were reported over time in fasting glucose, triglycerides and cholesterol blood levels, systolic and diastolic blood pressure, body weight, and BMI. Overall, a significant number of schizophrenic and bipolar patients treated with olanzapine showed ≥3 metabolic alterations in the first month of treatment when compared to those treated with haloperidol. Moreover, the number of olanzapine-treated patients developing metabolic changes in the first month was significantly higher in both diagnostic groups when compared to those who reached metabolic abnormal values in the subsequent 11 months. These data suggest that both antipsychotics could increase the metabolic risk in schizophrenic and bipolar patients with a higher prevalence in olanzapine-treated patients. On the other hand, olanzapine-treated patients seem to achieve metabolic abnormalities faster than haloperidol-treated subjects in both diagnostic groups.

show abstract

Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia

Cited by 10 publications

References 12 publications

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

Prevalência De Síndrome Metabólica Em Pacientes Com Esquizofrenia Refratária

Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients

Contact Info

Product

Resources

About